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Abstract
Objectives. Evidence regarding the cost-effectiveness of enhancing physical therapy exercise pro-
grammes in order to improve outcomes for patients with knee OA remains unclear. This study investi-
gates the cost-effectiveness of two enhanced physical therapy interventions compared with usual
physical therapy care (UC) for adults with knee OA.
Methods. A trial-based cost–utility analysis of individually tailored exercise (ITE) or targeted exer-
cise adherence (TEA) compared with UC was undertaken over a period of 18 months. Patient-level
costs were obtained, and effectiveness was measured in terms of quality-adjusted life years
(QALYs), allowing the calculation of cost per QALY gained from a base-case UK health-care
perspective.
Results. The UC group was associated with lower National Health Service (NHS) costs [ITE-UC:
£273.30, 95% CI: £62.10 to £562.60; TEA-UC: £141.80, 95% CI: £135.60 to £408.10)] and slightly
higher QALY gains (ITE-UC: 0.015, 95% CI: 0.057 to 0.026; TEA-UC: 0.003, 95% CI: 0.045 to
0.038). In the base case, UC was the most likely cost-effective option (probability<40% of ITE or
TEA cost-effective at £20 000/QALY). Differences in total costs were attributable to intervention
costs, number of visits to NHS consultants and knee surgery, which were higher in both ITE and
TEA groups.
Conclusion. This is the first economic evaluation comparing usual physical therapy care vs en-
hanced exercise interventions for knee OA that involves greater exercise individualization, supervision
and progression or that focuses on exercise and physical activity adherence over the longer term. Our
findings show that UC is likely to be the most cost-effective option.
Trial registration. Current Controlled Trials ISRCTN 93634563.
Trial protocol. Full details of the trial protocol can be found in the Supplementary Appendix, avail-
able with the full text of this article at http://www.biomedcentral.com/1471-2474/15/254 doi: 10.1186/
1471-2474-15-254
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Introduction
OA-related hip and knee pain are common and one of
the leading causes of disability and poor quality of life
among the elderly [1–3]. It is estimated that 23% of
adults aged 50 years report symptoms of severe pain
and disability [4]. Hip and knee OA are often significant
contributors to the economic burden on society, esti-
mated to account for between 1 and 2.5% of the gross
national product in countries including the USA,
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Canada, the UK, France and Australia [5–9]. Most of the
direct costs of knee OA are attributable to hospital
stays, specifically orthopaedic surgery, with 76 000 to-
tal knee replacement (TKR) procedures undertaken per
year in the UK [10]. Knee OA-related morbidity also
results in substantial indirect costs, estimated at £3.2
billion in the UK (1999–2000 prices), attributable to work
absenteeism and early retirement [11].
Given the socioeconomic impact of OA, there is a
strong rationale to test ways to improve patient out-
comes of pain and function and to ensure that health-
care systems make decisions about the use of resour-
ces based on high-quality evidence. Clinical trials and
systematic reviews consistently show the benefit of ex-
ercise therapy, in a variety of forms, for this patient
group [12–15]. Exercise is a low-cost treatment option,
which makes it accessible to many sufferers [16], and
different forms of exercise have been found to be cost-
effective in the USA [17], New Zealand [18] and Finland
[19]. In the UK, previous studies have demonstrated that
physical therapist-led exercise is cost-effective in the
short and long term [20–24]. However, the optimal exer-
cise regimen remains unclear, and there is currently lim-
ited evidence that patient outcomes can be improved by
offering enhanced physical therapist-led exercise pro-
grammes by greater focus on individualization, supervi-
sion and progression of lower-limb exercise or a greater
focus on long-term exercise and physical activity
adherence.
This study reports the economic evaluation conducted
alongside the Benefits of Effective Exercise for knee
Pain (BEEP) trial, to determine the cost-effectiveness of
two enhanced physical therapist-led exercise interven-
tions: (i) individually tailored exercise (ITE), and (ii) tar-
geted exercise adherence (TEA), in patients with knee
OA in primary care, compared with usual physical ther-
apy care (UC) [25–27].
Methods
Overview
The trial-based economic evaluation took the form of a
cost–utility analysis alongside a three parallel-group,
pragmatic, randomized controlled trial using quality-
adjusted life years (QALYs) as the benefit measure, over
an 18-month follow-up period. QALYs take into account
survival and quality of life, and the focus here was on
the potential for quality-of-life gains from a reduction in
pain and improvements in physical function from three
physical therapy-led exercise interventions. The primary
outcomes of the trial were lower-limb pain and function
measured using the WOMAC OA Index [28], and the
primary time point was 6 months after randomization.
Participants in the trial were recruited from 65 general
practices and five physical therapy services in the West
Midlands and Cheshire regions of the UK. Adults aged
45 years with current knee pain and/or stiffness in one
or both knees who met the criteria recommended by the
National Institute for Health and Care Excellence guide-
lines for a clinical diagnosis of knee OA [2] were invited
to take part. Full details of the trial methods are
provided in the published trial protocol [25]. The trial
was approved by the North West 1 Research Ethics
Committee, Cheshire UK (REC reference: 10/H1017/45),
and all participants gave informed consent to participate.
Interventions
All participants in the BEEP trial received an information
booklet providing information about benefits of exercise
and physical activity and a home exercise programme.
Usual physical therapy care (UC) included advice and
lower-limb exercise provided in up to four individual,
one-to-one treatment sessions over 12 weeks, in line
with usual physical therapy practice in the National
Health Service (NHS). The usual care arm of the BEEP
trial was developed following a national survey of cur-
rent physical therapy practice in the UK for knee OA
[27]. The other two groups received substantially en-
hanced care compared with UC. ITE involved a super-
vised, individually tailored and progressed lower-limb
exercise programme provided in six to eight one-to-one
treatment sessions over 12 weeks. Participants
received a print-out of a specific exercise prescription
individualized for them based on their progress on the
programme. TEA started with a focus on lower-limb ex-
ercise (as in the ITE protocol), with an aim to support
progress to increasing general physical activity adher-
ence over 6 months. It consisted of four individual face-
to-face treatments up to week 12, and a further 4–6
follow-up contacts (face-to-face or over the telephone)
from week 12 through to 6 months (a total of 8–10 treat-
ment contacts). More comprehensive details are
reported elsewhere [25–26].
Health outcomes
A questionnaire was administered to participants at
baseline, 3, 6, 9 and 18 months after randomization. The
questionnaire contained the EQ-5D 3L, a generic
Key messages
. Usual physical therapy care is likely to be the most cost-effective option for the management of knee OA.
. The cost-effectiveness of exercise interventions for knee OA beyond the 18-month follow-up in this
analysis remains unclear.
. Further research on long-term cost-effective exercise interventions among knee OA patients is needed.
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instrument measuring and valuing health-related quality
of life [29]. At each time point, the individual responses
to the EQ-5D questionnaire were converted to utility val-
ues [ranging from 0.594 (the worst health state) to
1.000 (full health), with 0 equivalent to death] obtained
using the UK value set, derived from a UK general pop-
ulation survey [30]. QALYs were then generated for each
individual using the area-under-the-curve approach that
links the participant utility scores at different time points
[31]. In order to avoid bias, adjustment for differences
between the groups in baseline EQ-5D scores was also
undertaken using a regression-based adjustment [32].
Resource use and cost analysis
In the base-case analysis, costs were measured from
the UK NHS perspective, with non-NHS health-care
costs incurred by the patient considered in sensitivity
analysis. Knee OA-related resource use data were col-
lected from self-report postal questionnaires adminis-
tered at 6 and 18 months. NHS resource use data
included primary care consultations [general practi-
tioners (GPs), practice nurses and community physical
therapists], consultations with other health-care profes-
sionals (e.g. hospital consultants, hospital physical
therapists and acupuncturists), hospital-based investiga-
tions (e.g. X-rays and MRI scans) and procedures (knee
joint-related injections, knee joint-related surgery such
as partial or total knee replacement or arthroscopy), and
prescribed medications. Additional information on any
knee surgery that had occurred or was scheduled to oc-
cur within the 18-month follow-up period was also occa-
sionally provided separately by participants via
telephone, during a consultation with BEEP trial physical
therapists (and therefore noted on a treatment case re-
port form) or written elsewhere on one of their returned
questionnaires, and this was also retrieved and included
in the cost analysis. Non-NHS (health-care) costs were
obtained by asking patients about their use of private
health care and purchase of over-the-counter medi-
cines, appliances and devices, treatments and use of lo-
cal exercise facilities. In order to assess broader
economic consequences of the interventions beyond
health-care resources, self-reported data on occupation
and time taken off work owing to their knee pain over
the 18-month period were also collected.
Information on resource use was also collected within
the trial to estimate participant-specific costs for the
intervention they received. Details of the number of trial-
related physical therapy sessions attended by each
participant were collected through treatment case report
forms (CRFs). Patients randomized to UC received
advice and a lower-limb exercise programme in up to
four treatment sessions within a period of 12 weeks.
The costs required to deliver the ITE and TEA interven-
tions included additional physical therapy sessions (in
both the ITE and TEA interventions), telephone contacts
and pedometers (in the TEA intervention). Intervention
costs included an average 47-min initial physical therapy
assessment and treatment session, followed by 28-min
face-to-face treatment sessions and 11-min telephone
call contacts in the TEA intervention (based on data
from CRFs for trial participants). Participants in all three
arms of the trial received an advice and information
booklet about knee OA; the cost of the advice and infor-
mation booklet was not included in the analysis because
it would not contribute to the incremental cost analysis
between the groups.
Unit costs were obtained from various sources, in-
cluding the British National Formulary [33] for the cost of
drugs, and the NHS Reference costs [34] and Unit
Costs of Health and Social Care [35] were applied to
other resource use items. All unit costs used in this
analysis are reported in Table 1, using a common 2012–
13 price year. We calculated indirect costs for time off
paid work using the human capital approach, based on
respondent job-specific wage estimates identified from
annual earnings data and UK Standard Occupational
Classification coding [36–38].
Statistical analysis
An incremental cost–utility analysis was conducted,
according to the intention-to-treat principle, to deter-
mine the difference in costs and QALYs between the
ITE and TEA groups compared with UC [39]. The unit of
outcome was the cost per additional QALY gained (in-
cremental costs divided by incremental QALYs). Multiple
imputation was used to impute all missing values for the
EQ-5D and total cost estimates for non-responders to
the 6- and 18-month follow-up questionnaires [40]. In
the base-case analysis, only NHS costs excluding sur-
gery were imputed. This was owing to some patients
providing information on knee surgery but not returning
a resource use questionnaire, resulting in missing re-
source use data. This additional knee surgery informa-
tion was used as part of a secondary analysis.
Confidence intervals for the mean differences in costs
were obtained by bias-corrected and accelerated non-
parametric bootstrapping, using 1000 replications [41].
Although costs were collected over an 18-month period,
discounting was not applied to the 18-month question-
naire data, as this contained resource use data from
both the last 6 months of year 1 and the first 6 months
of year 2 and could not be disaggregated. In order to
account for uncertainty, bootstrapping techniques were
used to derive 5000 paired estimates of mean
differential cost and QALY scores. The bootstrapped
cost-effect pairs were then graphically presented on
a cost-effectiveness plane [42,43]. Cost-effectiveness
acceptability curves were then calculated showing the
probability that an intervention was cost-effective at a
specific threshold of cost per QALY gained [44]. All sta-
tistical analyses were performed using Stata version
12.0 [45]. The base-case analysis was from a UK NHS
perspective, using the imputed dataset and adjusting for
baseline EQ-5D scores. Two sensitivity analyses were
performed to assess robustness of the findings. Firstly,
a complete-case analysis was undertaken to assess the
impact of missing cost and EQ-5D data. Secondly, the
Cost–utility analysis of exercise for knee OA
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imputed analysis was performed excluding the addi-
tional knee surgery-related costs. This was to assess
the impact of excluding costs calculated from additional
resource use information on knee replacement surgery
provided outside the health-care utilization section on
the follow-up questionnaires. Results were also pre-
sented from a health-care perspective, taking into ac-
count non-NHS health-care utilization. Finally, a
complete-case analysis of the impact of knee pain on
time off work was also reported, including calculation of
the monetary value of productivity losses.
Results
A total of 514 participants (UC: n¼ 175; ITE: n¼176;
and TEA: n¼ 163) with knee pain attributable to OA
formed the dataset for the analysis. All base-case analy-
sis reflects the imputed dataset unless stated otherwise.
Complete EQ-5D 3L outcome data at all time points
were available for 325 patients (64% of the total sam-
ple), and this sample was used as part of the sensitivity
analysis. At each of the time points, complete data were
available for 97% (baseline), 80% (3 months), 87% (6
months), 76% (9 months) and 78% (18 months) of par-
ticipants. The mean age of participants in the groups
was 63 years, with slightly more women (51%); and
slightly >42% were in paid employment. On average,
participants in the groups had moderate pain and dis-
ability, and there were no important differences between
groups at baseline.
Health outcomes
Mean EQ-5D scores at baseline and follow-up time
points and mean QALYs are shown in Table 2. Health-
related quality of life increased in all three intervention
groups from baseline to 3 months, and remained higher
than baseline scores at the 18-month follow-up. The ad-
justed and imputed mean QALYs over 18 months were
higher for the UC group than for the ITE or TEA groups,
but differences between intervention arms were very
small. This result did not change with the unadjusted or
complete-case analyses.
Resource use and costs
Table 3 shows the disaggregated details of mean re-
source use for participants with complete resource use
data. Over 18 months, only small differences in the up-
take of primary care and secondary care NHS services
were found between the three groups, with the excep-
tion of the number of visits to NHS consultants and
knee joint-related surgeries. The numbers of NHS con-
sultant visits were higher in both the ITE and TEA
groups, and the number of participants reporting TKR
was highest in the ITE group [10 TKR (7%) within 18
months] compared with the UC group [3 TKR (2%)] and
the TEA group [5 TKR (4%)]. In total, 50 (10%) BEEP
trial participants proceeded to visit NHS consultants for
their knee and 33 (6%) had knee joint-related surgery
over the 18-month follow-up period.
Less than half the patients in the trial were in paid em-
ployment at the 18-month follow-up; 43% in the UC
group and 34% in both the ITE and TEA groups. Data
TABLE 1 Health-care resource use unit costs
Health care resource Unit
cost (£)
Unit course
(reference)
Primary care contacts
GP consultation per 11.7
min
34 [35]
Practice nurse consultation
per hour
44 [35]
Nurse home visit per hour 60 [35]
Community physical
therapist per houra
30
Hospital-based care
Orthopaedic surgeon: first
attendance
128 [34]
Orthopaedic surgeon:
follow-up
102 [34]
Rheumatologist: first
attendance
202 [34]
Rheumatologist: follow-up 133 [34]
Acupuncturist: first
attendance
49 [34]
Acupuncturist: follow-up 44 [34]
Hospital physical therapist:
first attendanceb
49 [34]
Hospital physical therapist:
follow-upsb
44 [34]
Occupational therapist: first
attendance
75 [34]
Occupational therapist:
follow-up
68 [34]
Podiatrist: first attendance 74 [34]
Podiatrist: follow-up 68 [34]
Diagnostic tests: X-ray 35 [34]
Diagnostic test: MRI 169 [34]
Diagnostic test: CT scan 98 [34]
Surgery: knee replacement
major
5,676 [34]
Surgery: knee replacement
minor
2,221 [34]
Surgery: arthroscopy 2,942 [34]
Intervention costc [34]
First physical therapist
session: 47 min
23.5
Follow-up physical therapist
sessions: 28 min
14
Telephone physical therapy
consultation: 11 min
5.3
Pedometer 5
Prescribed medication Patient specific [33]
Medical investigations/
interventions
Patient specific [34]
aRelates to additional physical therapy visits via primary
care services.
bRelates to additional physical therapy visits accessed via
hospital-based care services.
cRelates to the unit cost used in costing the interventions
as part of the BEEP trial intervention. GP: general
practitioner.
Jesse Kigozi et al.
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on employment and time off work are reported in sup-
plementary Table S1, available at Rheumatology
Advances in Practice online. Of those who reported be-
ing in employment, only 2 (3%) patients in the UC group
reported time off paid work because of knee pain, com-
pared with 11 (24%) in the ITE group and 6 (15%) in the
TEA group. During the 18-month follow-up period, the
mean number of days off work was higher in the ITE
group (13.5 days) and the TEA group (6.9 days) than in
UC (1.8 days). This translated into higher productivity
costs in the ITE (£1313.60) and TEA groups (£691.00)
compared with UC (£127.80), and this difference was
significant. Overall, the ITE group was associated with
more days off work related to knee-related surgeries
than the TEA and UC groups (supplementary Table S1,
available at Rheumatology Advances in Practice online).
Table 4 shows the disaggregated mean (S.D.) health-
care costs per patient for each intervention and total
cost estimates for the imputed data analysis. The mean
costs per patient were £86 for TEA and £71 for ITE,
compared with £44 for UC. These costs reflect the
higher resource use in these categories in both the ITE
and TEA groups attributable to additional physical ther-
apy treatment sessions in the BEEP trial. Total mean
NHS costs over 18 months of follow-up were lower in
the UC group (£383) than in the ITE (£656) and TEA
(£524) groups (Table 4). The direction of this result did
not change when total health-care costs were consid-
ered or when a complete-case analysis was undertaken
(supplementary Table S2, available at Rheumatology
Advances in Practice online). The results from multiple
imputation of total NHS costs (rather than the base-case
imputation of all NHS costs excluding surgery) were also
in line with the base-case findings (supplementary
Table S2, available at Rheumatology Advances in
Practice online).
Cost–utility analysis
The base-case analysis showed that UC was slightly
more effective and less costly than ITE or TEA, resulting
in a position of dominance (Table 5). The cost-
effectiveness planes in Figs 1A and 1B confirm this
finding. In Fig. 1 (ITE vs UC), most cost–QALY difference
pairs (68%) are located in the north-west quadrant,
suggesting that UC is dominant over ITE. The cost-
effectiveness plane for TEA vs UC has 45% of cost–
QALY difference pairs in the north-west quadrant (Fig.
1B). The corresponding cost-effectiveness acceptability
curves (Fig. 1C) showed a low probability (<40%) of
either the ITE or TEA interventions being cost-effective
compared with UC if society was willing to pay up to
£20 000 per additional QALY.
Discussion
Our results demonstrate that usual NHS physical
therapy-led advice and exercise delivered in up to four
treatment sessions is likely to be the most cost-effective
use of health-care resources compared with either of
the enhanced physical therapy interventions (ITE or
TEA). Usual physical therapy care incurred lower costs
and was slightly more effective in terms of health-
related quality of life than the other interventions, with
TABLE 2 Outcomes by treatment group over 18 months
Variable UC ITE TEA
Primary imputed analysis n ¼ 175 n ¼ 176 n ¼ 163
EQ-5D scores, mean (S.D.)
Baseline 0.636 (0.230) 0.644 (0.229) 0.629 (0.229)
3 months 0.686 (0.201) 0.708 (0.188) 0.669 (0.227)
6 months 0.690 (0.225) 0.692 (0.215) 0.692 (0.217)
9 months 0.698 (0.217) 0.665 (0.249) 0.702 (0.199)
18 months 0.700 (0.219) 0.700 (0.206) 0.682 (0.232)
QALYs
Unadjusted, mean (S.D.) 1.035 (0.268) 1.026 (0.273) 1.026 (0.271)
Incremental QALYsb (95% CI) 0.009 (0.061 to 0.048) 0.009 (0.067 to 0.045)
Adjusteda 1.035 1.019 1.032
Incremental QALYsb (95% CI) 0.015 (0.057 to 0.026) 0.003 (0.045 to 0.038)
Complete-case analysis n ¼ 109 n ¼ 113 n ¼ 103
QALYs
Unadjusted, mean (S.D.) 1.058 (0.2687) 1.048 (0.206) 1.028 (0.2961)
Incremental QALYsb (95% CI) 0.010 (0.083 to 0.059) 0.029 (0.105 to 0.046)
Adjusteda 1.061 1.033 1.041
Incremental QALYsb (95% CI) 0.027 (0.084 to 0.029) 0.020 (0.078 to 0.037)
aPredicted scores after adjusting for outcome at baseline.
bITE-UC and TEA-UC. EQ-5D: EuroQol; ITE: individually tailored exercise; QALYs: quality-adjusted life years; TEA: targeted
exercise adherence; UC: usual physical therapy care.
Cost–utility analysis of exercise for knee OA
https://academic.oup.com/rheumap 5
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/2/rky018/5033574 by Keele U
niversity user on 18 February 2019
higher total QALYs at 18 months. As expected, the ITE
and TEA interventions were associated with higher treat-
ment costs resulting from more physical therapy ses-
sions. The results regarding outcomes are in line with
those found in the analysis of participants’ clinical out-
comes of pain and function. A further finding was a
higher rate of NHS consultant outpatient appointments
in both the ITE and TEA groups, and a greater number
of participants in the ITE group who had TKR surgery
within the 18-month follow-up period. This resulted in
more days off work in this patient group. This might be
attributable to patients having increased opportunities
through a greater number of physical therapy sessions
to discuss the appropriateness of other treatment
options and, in particular, the role of surgery. It might
also be explained by the greater number of treatment
sessions in the ITE group, through which there was
greater individualization and progression of exercise. It
is possible that for some patients this more intensive ex-
ercise programme highlighted their physical limitations
more clearly, prompting them to seek other health-care
advice and treatment as a result.
A review focused on cost-effectiveness of conserva-
tive management of hip and/or knee OA highlighted that
there was only limited cost-effectiveness evidence and
that more high-quality economic evaluations are needed
[46]. No previous trials had assessed the cost-
effectiveness of an enhanced programme of physical
therapy-led exercise that extends the number of treat-
ment sessions to allow greater exercise individualization,
supervision and progression or that focuses on exercise
and physical activity adherence over the longer term.
This is the first economic evaluation comparing these
enhanced interventions with usual physical therapy care
for knee OA. Two previous studies assessed the cost-
effectiveness of a package of up to 12 physical
therapist-led exercise sessions and found this to be
more cost-effective than usual GP-led care in the short
term (6 months), with some long-term benefits (12
months) [23,24]. In comparison, our analyses show that
TABLE 3 Health-care resource use per patient by treatment group over 18 months
UC ITE TEA
Resource category n5 141, mean (S.D.) n5 134, mean (S.D.) n5120, mean (S.D.)
Primary care: GP 1.42 (2.3) 1.50 (3.2) 1.33 (2.7)
Primary care: practice nurse 0.19 (0.7) 0.37 (1.7) 0.45 (2.3)
Primary care: other professionals 0.32 (1.3) 0.28 (1.4) 0.35 (1.6)
NHS consultant 0.93 (2.3) 1.68 (3.6)* 1.64 (4.2)**
NHS other health-care professionals 0.12 (0.6) 0.17 (0.9) 0.04 (0.2)
Private consultant 0.50 (2.8) 0.43 (2.1) 0.11 (0.8)
Private other health-care professionals 0.45 (0.5) 0.32 (3.1) 0.00 (–)
n (%) n (%) n (%)
Knee-related investigations and treatmenta 29 (21) 36 (27) 29 (24)
Total knee replacementb 3 (2) 10 (7) 5 (4)
Knee arthroscopyb 6 (4) 4 (3) 4 (3)
Partial knee replacementb 0 (–) 0 (–) 1 (1)
Prescribed medicationb n (%) n (%) n (%)
Simple analgesics 36 (26) 30 (22) 21 (18)
Moderate combination opioids 1 (1) 2 (1) 2 (2)
NSAIDs and COX-2 inhibitors 23 (16) 11 (8) 12 (10)
Strong combination opioids þ opioids 17 (12) 23 (17) 19 (16)
Very strong single opioids 0 (–) 1 (1) 1 (1)
Weak combination opioids 16 (11) 13 (10) 13 (11)
Over-the-counterb treatments n (%) n (%) n (%)
Simple analgesics 67 (48) 73 (54) 63 (53)
NSAIDs and COX-2 inhibitorsc 2 (1) 3 (2) 1 (1)
Weak combination opioidsd 4 (3) 8 (6) 5 (4)
aKnee-related investigations and treatments are investigations or treatments such as injections or X-rays, excluding knee-
related surgery.
bThe numbers (percentages) of participants reporting usage within the procedures, investigations, procedures, out-of-
pocket and prescribed medication categories are reported instead of mean (S.D.) because of multiple usage, purchases
and/or prescriptions.
cValues reported include selected NSAIDs that are available over the counter.
dValues reported include weak opioids available at low doses over the counter.
**P<0.1, *P<0.05 for UC vs ITE and UC vs TEA. GP: general practitioner; ITE: individually tailored exercise; NHS:
National Health Service; TEA: targeted exercise adherence; UC: usual physical therapy care; NSAIDs: Non-Steroidal Anti-
Inflammatory Drugs; COX-2 inhibitors: Cyclo-oxygenase-2 inhibitors.
Jesse Kigozi et al.
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greater exercise tailoring and targeting of physical activ-
ity adherence by physical therapists have additional
cost implications but are likely to generate only similar
effectiveness (based on QALYs) to up to four sessions
of usual physical therapy care.
This study has estimated that 6% of 514 patients in
primary care proceed to TKR within 18 months, and this
compares with 3% over 6 years and 10% over 10 years
in other comparable studies [47,48]. However there are
some limitations to our analysis. The amount of missing
data requiring imputation may be of concern, particularly
for the cost outcomes; only 64% of participants pro-
vided complete data at 18 months of follow-up. However,
imputation was done at all data collection time points
and a sensitivity analysis performed, which showed that
the results did not differ when a complete-case analysis
was undertaken. One reason for missing data might be
withdrawal from the trial or non-completion of question-
naires owing to knee surgery in the 18-month follow-up
period, a procedure associated with high costs to the
NHS. This might be attributable to patients being less
willing to complete a questionnaire if they feel that sur-
gery has resolved their problem. However, this was un-
likely to influence the results, as cost analyses with and
without the additional information we gathered on any
knee surgery both resulted in a greater number of partici-
pants in the ITE group having TKR. Resource use data
were requested from patients in their 18-month
TABLE 4 Mean (S.D.) costs per participant by treatment group over 18 months, unless otherwise stated
UC ITE TEA
n5175 n5 176 n5 163
Complete-case analysis n ¼ 141 (£) n ¼ 134 (£) n ¼ 120 (£)
Intervention cost (£) 43.9 (20.8) 70.8 (32.9)* 85.9 (41.7)*
Primary care
GP consultations 34.5 (55.3) 36.7 (73.8) 34.7 (71.7)
Practice nurse consultations 2.5 (8.7) 5.2 (27.1) 6.3 (33.9)
Consultations with other professionals 5.9 (34.9) 4.7 (32.4) 7.0 (35.6)
Prescriptions 7.6 (17.4) 7.6 (21.7) 4.8 (9.6)
Secondary care
NHS consultant 67.1 (191.1) 106.3 (231.4) 103.9 (250.4)
Consultation with other NHS professional 0.00 (–) 3.3 (19.3)** 1.4 (12.4)
Knee surgerya 213.8 (1194.5) 389.4 (1501.5) 259.9 (1118.6)
NHS investigations and treatmentsb 15.4 (51.6) 16.31 (48.9) 16.7 (64.3)
Private consultant 26.8 (149.2) 30.9 (166.8) 8.2 (46.1)
Consultation with other private health-care
professional
0.0 (–) 13.8 (138.1) 0.0 (–)
Over-the-counter purchasesc 17.6 (72.3) 16.8 (44.5) 28.9 (133.3)
Base-case analysis (imputed) n ¼ 175 n ¼ 176 n ¼ 163
Total NHS cost, £ 382.6 (1351.3) 656.0 (1617.1) 524.4 (1258.2)
Adjusted mean difference (95% CI) – 273.3 (62.1 to 562.6) 141.8 (135.6 to 408.1)
Total health-care costs, £ 427.2 (1457.8) 711.1 (1683.7) 560.4 (1307.1)
Adjusted mean difference (95% CI) – 283.9 (73.4 to 591.6) 133.2 (178.3 to 410.7)
aKnee surgery includes all full knee replacement, partial knee replacement and arthroscopic surgical procedures.
bNHS investigations and treatments are investigations or treatments such as injections or X-rays, excluding knee-related
surgery.
cIncludes treatments or appliances bought over the counter.
**P<0.1, *P<0.05 for UC vs ITE and UC vs TEA. GP: general practitioner; ITE: individually tailored exercise; NHS:
National Health Service; TEA: targeted exercise adherence; UC: usual physical therapy care.
TABLE 5 Cost–utility analysis for 18 months of follow-up
Intervention Costs [mean (S.D.); (£)] Mean QALYs ICER (£/QALY gained)
UC 382.6 (1351.3) 1.035 –
ITE 656.0 (1617.1) 1.032 Dominated by usual care
TEA 524.4 (1258.2) 1.019 Dominated by usual care
–A value for an ICER is not relevant here. ICER: incremental cost-effectiveness ratio; ITE: individually tailored exercise;
QALY: quality-adjusted life year; TEA: targeted exercise adherence; UC: usual physical therapy care.
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questionnaire, requiring recall of resource use over the
previous 12 months, and this length of time might have
resulted in inaccurate estimates. However, this was the
case for patients in all three trial groups, so it is likely any
inaccuracies are balanced. The trial included participants
from many primary care general practices; therefore the
findings are generalizable to the wider population of pri-
mary care patients with knee OA in the UK. However, the
interventions in this trial were compared with usual physi-
cal therapy practice in the UK [25–27], and the findings
may not be generalizable to other countries or health sys-
tems with different usual care programmes.
This economic evaluation demonstrated that neither
increasing the individual tailoring of, nor targeting the
adherence to exercise and physical activity in older
adults with knee OA is likely to be cost-effective
compared with usual physical therapy care. The clinical
results showed that 50% of patients could be classi-
fied as treatment responders in the BEEP trial; therefore,
further health economics research is needed that inves-
tigates how best to use health-care resources for adults
with knee OA. Our findings show that usual physical
therapy care is likely to be the most cost-effective
option.
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